pharmaphorum

OCTOBER 20, 2021

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78

Trials Genome Genomics Bioinformatics 78

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. executive vice president of Research and Development at Amgen. billion in cash.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

OCTOBER 3, 2022

He holds a PhD in Medicine from Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University. Richmond is a mathematician with over 20 years’ experience of developing digital solutions to problems in drug discovery and development. Fellowship Programme. Fellowship Programme.

Drugs 52

Drugs Scientist Bioinformatics Medicine 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 4, 2022

Throughout 2022, Exscientia has progressed AI-driven capabilities for virtual biologics design, such as human antibodies, and is now establishing an automated biologics laboratory in Oxford to internally generate and profile novel antibodies. . The binding site of the antibody consists of two chains (heavy and light).

Antibody 52

Antibody Bioinformatics Engineer Protein 52

Drug Discovery World

NOVEMBER 15, 2022

Known for its ability to offer precision and flexibility while expanding the experimental scale, synthetic biology tools can reduce development timelines and costs, and lend a competitive advantage over traditional methods. . Synthetic libraries for antibody drug discovery . Rapid and accurate DNA synthesis .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows.

Antibody 59

Antibody Protein Engineer In-Vivo 59

The Pharma Data

SEPTEMBER 1, 2020

head of Immunology and Fibrosis Development, Bristol Myers Squibb. Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Presentation Topic: Biomarkers and Bioinformatics. Consider interruption of treatment with ZEPOSIA if a patient develops a serious infection. Author: Selmaj. Author: Healy.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52

Drug Discovery World

APRIL 29, 2024

He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021. Hall has been with the company for more than 16 years, including as Chief Commercial Officer, and was previously Head of Business Development in Europe for Cyprotex.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments. percent show less reliability).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Figure 2: Advanced data visualisation examples for transcriptomics data.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . From there, they evaluate what kind of antibodies are produced. ” The Application .

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Drug Discovery World

SEPTEMBER 7, 2022

By Ashoka Rajendra , Head of Development & Manufacturing Products at Benchling. From discovery, to lead optimsation, process development, pre-clinical, and even investigational new drug filings, each stage of R&D stands to benefit from AI. .

Scientist 52

Scientist Life Science Antibody Protein 52

Drug Discovery World

APRIL 21, 2023

Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology. It will be led by Björn C.

Doctors 52

Doctors Doctor Genetics In-Vitro 52